3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
13
Colorectal Neoplasms
9
Neoplasm Metastasis
8
Peritoneal Neoplasms
6
Pancreatic Neoplasms
6
Non-Muscle Invasive Bladder Neoplasms
6
Appendiceal Neoplasms
6
Stomach Neoplasms
5
Carcinoma, Hepatocellular
5
Anus Neoplasms
5
Sarcoma
4
Rectal Neoplasms
4
Colonic Neoplasms
4
Liver Neoplasms
3
Carcinoma, Transitional Cell
3
Pseudomyxoma Peritonei
2
Mesothelioma, Malignant
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Anal Canal Carcinoma
2
Urothelial Carcinoma of the Bladder
1
Urologic Neoplasms
1
Urologic Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pleural Neoplasms
1
Pancoast Syndrome
1
Interventions
Pemetrexed
10
Cisplatin
9
Gemcitabine
8
Nivolumab
5
Ipilimumab
4
Carboplatin
4
niraparib
3
durvalumab
3
Vinorelbine
3
Bevacizumab
3
tremelimumab
2
pembrolizumab
2
olaparib
2
anetumab ravtansine
2
Radiotherapy, Intensity-Modulated
2
Oxaliplatin
2
Imatinib Mesylate
2
Hyperthermic Intraperitoneal Chemotherapy
2
Fluorodeoxyglucose F18
2
Cytoreduction Surgical Procedures
2
vandetanib
1
tislelizumab
1
tazemetostat
1
spartalizumab
1
sargramostim
1
ribociclib
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
defactinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Mesothelioma
×
Mitomycin
×
Clear all
NCT00454519
2009-02-13
IPHC
Wuhan University
Phase 2
Unknown
60 enrolled